Tartaric Acid
Medchemexpress LLC HY-N2522 5mg Medchemexpress, Carboxyatractyloside (dipotassium) CAS:33286-30-5 Purity:>98%
Medchemexpress, HY-N2522 5mg Carboxyatractyloside (dipotassium) CAS:33286-30-5 Carboxyatractyloside dipotassium is a toxic natural product, acts as an inhibitor of ADP/ATP carrier, inhibits mitochondrial ADP/ATP transport. Purity:>98% Medchemexpress has over 10000 novel life-science reagents, reference compounds, APIs and natural compounds for laboratory and scientific use. Other quantity can also be offered.
Sigma Aldrich meso-Tartaric acid monohydrate
MilliporeSigma Sigma Organics products encompass a wide range of quality reagents, solvents, catalysts, and building blocks for organic synthesis. From benchtop discovery to process development and scale-up, Sigma Organics solutions are built to meet the needs of synthetic chemists.
Sigma Aldrich DL-Tartaric acid
MilliporeSigma Sigma Organics products encompass a wide range of quality reagents, solvents, catalysts, and building blocks for organic synthesis. From benchtop discovery to process development and scale-up, Sigma Organics solutions are built to meet the needs of synthetic chemists.
GFS Chemicals Inc SODIUM TARTRATE, DIHYDRATE, REAGENT (ACS) | 100 G | GFS CHEMICALS, INC. Item #: 69356 | Bulk #: 805
SODIUM TARTRATE, DIHYDRATE, REAGENT (ACS) | Chemical Formula : Na!2C!4H!4O!6.2H!2O | CAS # : 6106-24-7 | Specifications : Ammonium 0.003 % , Assay 99.0 - 101.0 %, Calcium 0.01 % , Chloride 0.0005 % , Heavy metals (as Pb) 0.0005 % , Insoluble Matter 0.005 % , Iron 0.001 % , Loss on drying @ 150 C 15.61 - 15.71 %, pH of 5% solution @ 25 C 7.0 - 9.0 pH, Phosphate 0.0005 % , Sulfate 0.005 %
Medchemexpress LLC D-(-)-tartaric acid diisopropyl ester | 62961-64-2 | MFCD00008876 | >98.0% | 234.25 g/mol | C10H18O6 | 25 G
D-(-)-Tartaric acid diisopropyl ester (CAS 62961-64-2) is a chiral organic reagent used in enantioselective synthesis, biochemical assays, and research applications. It is a colorless to light yellow liquid with formula C10H18O6 and molecular weight 234.25 g/mol, supplied in laboratory pack sizes for analytical and synthetic use. Intended for research use only.
- Chiral building block for asymmetric synthesis
- Suitable for biochemical assays and method development
- High purity, typically >98%
- Available in multiple laboratory pack sizes
- Stored at low temperatures to maintain stability
Apexbio Technology LLC ENMD-2076 934353-76-1 5mg
ENMD-2076 (CAS 934353-76-1) is a selective inhibitor of Aurora A kinase (IC50 14 nM) and FLT3 (IC50 1 86 nM) with additional inhibitory activity against multiple tyrosine kinases implicated in angiogenesis and cell proliferation including RET FLT4/VEGFR3 SRC CSF1R NTRK1 FGFR1/2 VEGFR2/KDR LCK and PDGFR (IC50 1 86 120 nM) ENMD-2076 disrupts cell cycle progression by arresting cells in the G2/M phase through inhibition of Aurora kinases suppresses the PI3K/AKT signaling pathway and demonstrates cytotoxic effects in hematologic malignancy and solid tumor cell lines (in vitro IC50 25 700 nM) In vivo it reduces tumor growth and angiogenesis in xenograft models supporting its use in cancer research and antiangiogenic studies
Apexbio Technology LLC ENMD-2076 934353-76-1 10mM (in 1mL DMSO)
ENMD-2076 (CAS 934353-76-1) is a selective inhibitor of Aurora A kinase (IC50 14 nM) and FLT3 (IC50 1 86 nM) with additional inhibitory activity against multiple tyrosine kinases implicated in angiogenesis and cell proliferation including RET FLT4/VEGFR3 SRC CSF1R NTRK1 FGFR1/2 VEGFR2/KDR LCK and PDGFR (IC50 1 86 120 nM) ENMD-2076 disrupts cell cycle progression by arresting cells in the G2/M phase through inhibition of Aurora kinases suppresses the PI3K/AKT signaling pathway and demonstrates cytotoxic effects in hematologic malignancy and solid tumor cell lines (in vitro IC50 25 700 nM) In vivo it reduces tumor growth and angiogenesis in xenograft models supporting its use in cancer research and antiangiogenic studies
Apexbio Technology LLC ENMD-2076 934353-76-1 200mg
ENMD-2076 (CAS 934353-76-1) is a selective inhibitor of Aurora A kinase (IC50 14 nM) and FLT3 (IC50 1 86 nM) with additional inhibitory activity against multiple tyrosine kinases implicated in angiogenesis and cell proliferation including RET FLT4/VEGFR3 SRC CSF1R NTRK1 FGFR1/2 VEGFR2/KDR LCK and PDGFR (IC50 1 86 120 nM) ENMD-2076 disrupts cell cycle progression by arresting cells in the G2/M phase through inhibition of Aurora kinases suppresses the PI3K/AKT signaling pathway and demonstrates cytotoxic effects in hematologic malignancy and solid tumor cell lines (in vitro IC50 25 700 nM) In vivo it reduces tumor growth and angiogenesis in xenograft models supporting its use in cancer research and antiangiogenic studies
Apexbio Technology LLC ENMD-2076 934353-76-1 50mg
ENMD-2076 (CAS 934353-76-1) is a selective inhibitor of Aurora A kinase (IC50 14 nM) and FLT3 (IC50 1 86 nM) with additional inhibitory activity against multiple tyrosine kinases implicated in angiogenesis and cell proliferation including RET FLT4/VEGFR3 SRC CSF1R NTRK1 FGFR1/2 VEGFR2/KDR LCK and PDGFR (IC50 1 86 120 nM) ENMD-2076 disrupts cell cycle progression by arresting cells in the G2/M phase through inhibition of Aurora kinases suppresses the PI3K/AKT signaling pathway and demonstrates cytotoxic effects in hematologic malignancy and solid tumor cell lines (in vitro IC50 25 700 nM) In vivo it reduces tumor growth and angiogenesis in xenograft models supporting its use in cancer research and antiangiogenic studies
Apexbio Technology LLC ENMD-2076 934353-76-1 10mg
ENMD-2076 (CAS 934353-76-1) is a selective inhibitor of Aurora A kinase (IC50 14 nM) and FLT3 (IC50 1 86 nM) with additional inhibitory activity against multiple tyrosine kinases implicated in angiogenesis and cell proliferation including RET FLT4/VEGFR3 SRC CSF1R NTRK1 FGFR1/2 VEGFR2/KDR LCK and PDGFR (IC50 1 86 120 nM) ENMD-2076 disrupts cell cycle progression by arresting cells in the G2/M phase through inhibition of Aurora kinases suppresses the PI3K/AKT signaling pathway and demonstrates cytotoxic effects in hematologic malignancy and solid tumor cell lines (in vitro IC50 25 700 nM) In vivo it reduces tumor growth and angiogenesis in xenograft models supporting its use in cancer research and antiangiogenic studies
Medchemexpress LLC Racemic anatabine | 2743-90-0 | MFCD00078278 | 99.7% | 160.22 | C10H12N2 | 50MG
Racemic anatabine is a high-purity reference standard of the tobacco alkaloid anatabine (CAS 2743-90-0) supplied for research and analytical use. It is intended for laboratory applications such as use as a marker of tobacco exposure and for biochemical or neuroscience studies. The material is provided as a solid with recommended cold-storage conditions and is available in multiple pack sizes, including 50 MG.
- High purity (≈99.7%) for analytical and reference use.
- Suitable as a marker of tobacco exposure in analytical assays.
- Molecular formula C10H12N2; molecular weight 160.22.
- Available in multiple pack sizes, including 50 MG.
- Store solid at -20°C for long-term stability; follow solvent storage guidance.
- Intended for research use only; not for human use.
Medchemexpress LLC HY-Y0293 500mg Medchemexpress, L-Tartaric acid CAS:87-69-4 Purity:>98%
Medchemexpress, HY-Y0293 500mg L-Tartaric acid CAS:87-69-4 L-Tartaric acid (L-(+)-Tartaric acid) is an endogenous metabolite. Purity:>98% Medchemexpress has over 10000 novel life-science reagents, reference compounds, APIs and natural compounds for laboratory and scientific use. Other quantity can also be offered.